argenx SE (LON:0QW0)

London flag London · Delayed Price · Currency is GBP · Price in EUR
713.48
+5.87 (0.83%)
At close: Jan 30, 2026
12.22%
Market Cap37.30B +16.8%
Revenue (ttm)2.74B +93.0%
Net Income1.14B
EPS17.31
Shares Outn/a
PE Ratio32.70
Forward PE27.97
Dividendn/a
Ex-Dividend Daten/a
Volume17,200
Average Volume29,466
Open701.00
Previous Close707.61
Day's Range701.60 - 717.40
52-Week Range456.80 - 809.80
Beta-0.13
RSI51.55
Earnings DateFeb 25, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,599
Stock Exchange London Stock Exchange
Ticker Symbol 0QW0
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements